NewEdge Advisors’s Roivant Sciences ROIV Stock Holding History

NewEdge Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-80	Closed	-$2.22K	–	4348
2026 Q1	$2.22K	Buy	+80	New	+$2.06K	﹤0.01%	3789

Other funds holding ROIV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $646M AUM 291.07% 1-Year Est. Return

NewEdge Advisors's ROIV Position: Q2 2026 in Review

NewEdge Advisors sold out of Roivant Sciences (ROIV) in Q2 2026, closing a stake of 80 shares — an estimated $2.22K sold.

NewEdge Advisors first reported a position in ROIV in Q1 2026 and held it in 1 quarter. The position peaked at $2.22K in Q1 2026. 371 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

NewEdge Advisors reported no remaining Roivant Sciences position as of Q2 2026 after selling out during the quarter.
NewEdge Advisors sold 80 Roivant Sciences shares in Q2 2026, an estimated $2.22K.
NewEdge Advisors first reported a position in Roivant Sciences in Q1 2026 and held it in 1 quarter.
NewEdge Advisors's Roivant Sciences position peaked at $2.22K in Q1 2026.
371 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.